Celine Halioua On The Science and Business of Making Dogs Live Longer

Celine Halioua, Founder & CEO of Loyal, joins Village Global VP Sam Kirschner to discuss her journey building a biotech company developing the first FDA-approved drugs for lifespan extension – going dogs first. Loyal has raised over $250M and recently closed its Series C after clearing major regulatory milestones on both efficacy and safety. In this conversation, Celine breaks down why you can't develop a human longevity drug today (and it's not because of biology – it's logistics and financial norms), why dogs are the fastest path to getting there, and how milestone-based fundraising works for deep tech companies that are years from revenue. She also shares hard-won lessons on understanding the incentives of the people around you, taking people as they are, and staying emotionally unattached to the how while staying committed to the what. Loyal: Celine on X: Thanks for listening – if you like what you hear, please review us on your favorite podcast platform. Check us out on the web at or get in touch with us on X @villageglobal. Want to get updates from us?

You can listen to Celine Halioua On The Science and Business of Making Dogs Live Longer online on Radio and Podcast. Open the player on this page to stream the available audio.

Celine Halioua On The Science and Business of Making Dogs Live Longer is an episode from Venture Stories by Village Global.

This episode is 00:53:08 long.

This episode was published on Feb 11, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Venture Stories when more episodes are available from the podcast feed.